Metabolomics Applications in Gynecological Oncology

The application of metabolomics in gynecological oncology has transformed our understanding of tumour biology by enabling comprehensive analysis of small-molecule metabolites within cells, tissues and biofluids. High-resolution mass spectrometry, nuclear magnetic resonance spectroscopy and chromatography-based platforms now allow detection of hundreds to thousands of metabolites, revealing perturbations in pathways of energy metabolism, amino-acid turnover, lipid synthesis and redox homeostasis. In ovarian, cervical and endometrial cancers, metabolomic profiling has identified distinct biomarker signatures for early detection, prognostic stratification and treatment monitoring. Altered lipid and fatty-acid species have served both as diagnostic markers and predictors of chemoresistance, while perturbations in glutamine and tryptophan catabolism have informed novel therapeutic targets. Integration with transcriptomics and proteomics has uncovered dysregulated networks that drive tumour growth and metastasis, offering opportunities for personalised medicine. Clinically, metabolomics has enabled non-invasive screening assays with superior accuracy to traditional markers, real-time assessment of surgical efficacy and relapse detection, and mechanistic insights into drug action and resistance. As analytical sensitivity and computational methods advance, metabolomics stands poised to deliver precision diagnostics and targeted interventions across the global burden of gynecological malignancies.

Research from Nature Portfolio

Recent studies have coupled large-scale metabolomic profiles with complementary omic layers to refine diagnostic and prognostic models in cervical and ovarian cancer. An integrated metabolomics–transcriptomics analysis of cervical tumour samples elucidated a network of over fifty altered metabolites, pinpointing five candidate biomarkers that distinguished neoplastic from normal tissue with near-perfect accuracy and revealed metabolic nodes amenable to therapeutic intervention. In ovarian cancer, high-performance mass spectrometry supported the construction of a sixteen-metabolite support vector machine classifier that achieved complete separation of early-stage cases from healthy controls. Further work in epithelial ovarian carcinoma employed rapid-resolution liquid chromatography–mass spectrometry to map metabolic shifts associated with primary disease, cytoreductive surgery and relapse, identifying distinct signatures of lipid dysregulation, oxidative stress and amino-acid turnover that track disease progression and treatment response.

Metabolomics Applications in Gynecological Oncology publication trend

The graph below shows the total number of articles in metabolomics applications in gynecological oncology across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: The comprehensive analysis of small-molecule metabolites in biological samples, reflecting cellular processes and disease states.

Biomarker: A measurable molecular indicator of normal or pathological biological activity, used for diagnosis, prognosis or therapeutic monitoring.

Mass spectrometry: An analytical technique that ionises chemical species and sorts the ions based on their mass-to-charge ratio to identify and quantify molecules.

Lipidomics: A sub-discipline of metabolomics focused on the systematic study of lipid species and their roles in health and disease.

Support vector machine: A supervised machine-learning algorithm that constructs hyperplanes in a multidimensional space to classify data points.

Area under the curve (AUC): A metric for evaluating the performance of diagnostic tests, representing the probability that the test will correctly distinguish between diseased and non-diseased states.

References

1. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer. Scientific Reports (2017).
2. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics (2009).
3. Metabolic phenotyping for monitoring ovarian cancer patients. Scientific Reports (2016).
4. A metabolomic approach to identifying platinum resistance in ovarian cancer. Journal of Ovarian Research (2015).
5. Identification and validation of serum metabolite biomarkers for endometrial cancer diagnosis. EMBO Molecular Medicine (2024).
6. Identification of predictive biomarkers for endometrial cancer diagnosis and treatment response monitoring using plasma metabolome profiling. Cancer & Metabolism (2023).
7. LC/MS-Based Polar Metabolite Profiling Identified Unique Biomarker Signatures for Cervical Cancer and Cervical Intraepithelial Neoplasia Using Global and Targeted Metabolomics. Cancers (2019).